SEARCH

SEARCH BY CITATION

References

  • 1
    Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853860.
  • 2
    Mohsen AH, Easterbrook P, Taylor CB, Norris S. Hepatitis C and HIV-1 co-infection. Gut 2002; 51: 18.
  • 3
    Puoti M, Spinetti A Ghezzi A, Donato F, Zaltron S, Pulzolu V, et al. Mortality from liver disease in patients with HIV infection: A cohort study. J Acquir Immune Defic Syndr 2000; 24: 211217.
  • 4
    Rica I, McGovern B, Dhar R, Stone D. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 49297.
  • 5
    Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosador R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 14.
  • 6
    Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as a common pathway. AIDS 1998; 12: 17351744.
  • 7
    Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002; 35: 182189.
  • 8
    Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in HIV-infected patients: Report of 12 cases and review of the literature. Clin Infect Dis 2002; 34: 838846.
  • 9
    Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactemia and lactic acidosis during antiretroviral therapy; relevance, reproducibility, and possible risk factor. AIDS 2002; 16: 13411349.
  • 10
    Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 14231430.
  • 11
    Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in ten HIV-infected patients taking multiple nucleoside analogues. Clin Infect Dis 2000; 31: 162166.
  • 12
    Bonnet F, Bonarek M, Morlat P, Mercie P, Dupon M, Germain MC, et al. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: A case-control study. Clin Infect Dis 2003; 36: 13241328.
  • 13
    Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalised antiretroviral-treated patients with HIV infection: a report of 12 cases. Clin Infect Dis 2001; 33: 19141921.
  • 14
    Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in HIV-infected patients: A pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 15
    European MMF Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3 year results from the placebo-controlled trial. Transplantation 1999; 68: 391396.
  • 16
    Hossain MM, Coull JJ, Drusano GL, Margolis DM. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antivir Res 2002; 55: 4152.
  • 17
    Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002; 31: 4549.
  • 18
    Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G, Grisorio B, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: Ultrastructural and biochemical changes. Am J Gastroenterol 1999; 94: 20032005.
    Direct Link:
  • 19
    Adinolfi LE, Gambardella M, Andreana A, Tripodi M-F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 13581364.
  • 20
    Cote H, Brumme Z, Craib K, Alexander C, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811820.